Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2013 1
2014 1
2016 3
2017 3
2018 4
2019 4
2020 4
2021 1
2022 1
2023 1
2024 2
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z, You Y, Griffin N, Feng J, Shan F. Li Z, et al. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Int Immunopharmacol. 2018. PMID: 29885638 Review.
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and signi …
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to …
Experience and prospects for the use of off-label drugs in oncology.
Drogovoz SM, Starikov VI, Ivantsyk LB, Shchokina KG. Drogovoz SM, et al. Exp Oncol. 2021 Mar;43(1):1-5. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-1.15583. Exp Oncol. 2021. PMID: 33785726
An example of an off-label prescription is anxiolytic medicine lorazepam, which can be used off-label as an antiemetic in cancer patients. Low doses of naltrexone are applied to treat cancer and autoimmune diseases. A retrospective analysis of modern oncotherapy indicates …
An example of an off-label prescription is anxiolytic medicine lorazepam, which can be used off-label as an antiemetic in cancer patients. L …
Off-label Use of Lamotrigine and Naltrexone in the Treatment of Ketamine Use Disorder: A Case Report.
Avra T, Vasudevan F, Mukherjee R, Morton I, Samuels EA. Avra T, et al. J Addict Med. 2025 Jan-Feb 01;19(1):112-114. doi: 10.1097/ADM.0000000000001359. Epub 2024 Aug 5. J Addict Med. 2025. PMID: 39101571
He resumed use after an initial period of abstinence and was subsequently started on lamotrigine and naltrexone for treatment of depressive symptoms and cravings. This combination altered his experience while on ketamine, resulting in nausea and decreased hallucinogenic ef …
He resumed use after an initial period of abstinence and was subsequently started on lamotrigine and naltrexone for treatment of depr …
Pharmacotherapy of alcoholism - an update on approved and off-label medications.
Soyka M, Müller CA. Soyka M, et al. Expert Opin Pharmacother. 2017 Aug;18(12):1187-1199. doi: 10.1080/14656566.2017.1349098. Epub 2017 Jul 24. Expert Opin Pharmacother. 2017. PMID: 28658981 Review.
Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase …
Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter i …
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
Fairbanks J, Umbreit A, Kolla BP, Karpyak VM, Schneekloth TD, Loukianova LL, Sinha S. Fairbanks J, et al. Mayo Clin Proc. 2020 Sep;95(9):1964-1977. doi: 10.1016/j.mayocp.2020.01.030. Epub 2020 May 20. Mayo Clin Proc. 2020. PMID: 32446635 Review.
There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, naltrexone (oral and long-acting injectable), and acamprosate. Of growing interest is the use of anticonvulsants for the treatment of al …
There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, …
Pharmacologic interventions for alcohol use disorder.
Menge J, Evitt B. Menge J, et al. JAAPA. 2025 Jun 1;38(6):e2-e6. doi: 10.1097/01.JAA.0000000000000106. Epub 2025 May 27. JAAPA. 2025. PMID: 40421949 Review.
It is therefore important to examine multiple avenues for successful cessation and continued abstinence. Disulfiram, oral naltrexone, naltrexone IM, and acamprosate are currently the only four medications approved for the treatment of AUD by the FDA. ...
It is therefore important to examine multiple avenues for successful cessation and continued abstinence. Disulfiram, oral naltrexone, …
Low Dose Naltrexone in Dermatology.
Jaros J, Lio P. Jaros J, et al. J Drugs Dermatol. 2019 Mar 1;18(3):235-238. J Drugs Dermatol. 2019. PMID: 30909326
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn's disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and m …
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of condi …
The lowdown on low-dose naltrexone.
Shabeeb N. Shabeeb N. Cutis. 2020 Jan;105(1):E17-E18. Cutis. 2020. PMID: 32074159
Low-dose naltrexone (LDN) has become a hot topic in many fields of medicine, including dermatology. ...
Low-dose naltrexone (LDN) has become a hot topic in many fields of medicine, including dermatology. ...
Medical treatment of alcohol dependence: a systematic review.
Miller PM, Book SW, Stewart SH. Miller PM, et al. Int J Psychiatry Med. 2011;42(3):227-66. doi: 10.2190/PM.42.3.b. Int J Psychiatry Med. 2011. PMID: 22439295 Free PMC article.
RESULTS: A total of 85 studies, representing 18,937 subjects, met our criteria for inclusion. The evidence base for oral naltrexone (6% more days abstinent than placebo in the largest study) and topiramate (prescribed off-label) (e.g., 26.2% more days abstinent than placeb …
RESULTS: A total of 85 studies, representing 18,937 subjects, met our criteria for inclusion. The evidence base for oral naltrexone ( …
Off-label use of baclofen for alcohol use disorders in India: no ethics without science.
Braillon A, Naudet F. Braillon A, et al. Indian J Med Ethics. 2025 Oct-Dec;X(4):311-312. doi: 10.20529/IJME.2025.044. Indian J Med Ethics. 2025. PMID: 41195930 Free article.
Off-label use of baclofen is the preferred pharmacotherapy for alcohol use disorders in India, despite its negative benefit/harm ratio, and the fact that acamprosate or naltrexone have long been established as robustly evidence-based medicines. This unacceptable state of a …
Off-label use of baclofen is the preferred pharmacotherapy for alcohol use disorders in India, despite its negative benefit/harm ratio, and …
27 results